1. Home
  2. HPQ vs GMAB Comparison

HPQ vs GMAB Comparison

Compare HPQ & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HP Inc.

HPQ

HP Inc.

HOLD

Current Price

$25.35

Market Cap

19.8B

Sector

Technology

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$26.89

Market Cap

16.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HPQ
GMAB
Founded
1939
1999
Country
United States
Denmark
Employees
N/A
3088
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.8B
16.5B
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
HPQ
GMAB
Price
$25.35
$26.89
Analyst Decision
Hold
Strong Buy
Analyst Count
12
8
Target Price
$21.42
$39.56
AVG Volume (30 Days)
13.8M
1.9M
Earning Date
05-27-2026
05-07-2026
Dividend Yield
5.96%
N/A
EPS Growth
N/A
N/A
EPS
0.58
N/A
Revenue
$55,295,000,000.00
N/A
Revenue This Year
$3.10
$17.85
Revenue Next Year
$0.39
$16.04
P/E Ratio
$37.91
$1.90
Revenue Growth
3.24
N/A
52 Week Low
$17.56
$20.23
52 Week High
$29.55
$35.43

Technical Indicators

Market Signals
Indicator
HPQ
GMAB
Relative Strength Index (RSI) 76.83 49.41
Support Level $18.00 $25.34
Resistance Level $26.04 $29.64
Average True Range (ATR) 1.04 0.75
MACD 0.22 0.05
Stochastic Oscillator 96.82 52.21

Price Performance

Historical Comparison
HPQ
GMAB

About HPQ HP Inc.

HP (formerly Hewlett-Packard) is a behemoth in the PC and printing markets. It has focused on these markets since it exited IT infrastructure in 2015 with the split from Hewlett Packard Enterprise. HP focuses on the commercial market, but maintains sales of consumer devices and printers. The firm has a broad and global customer base, with only one third of sales coming from the US. HP completely outsources manufacturing and relies heavily on channel partners for its sales and marketing.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: